Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Jan;27(1):151-153.
doi: 10.1038/cr.2016.102. Epub 2016 Aug 30.

Structural basis of anti-PD-L1 monoclonal antibody avelumab for tumor therapy

Kefang Liu  1   2 , Shuguang Tan  3 , Yan Chai  3 , Danqing Chen  3 , Hao Song  4 , Catherine Wei-Hong Zhang  5 , Yi Shi  3 , Jun Liu  1   2 , Wenjie Tan  1   2 , Jianxin Lyu  1 , Shan Gao  6 , Jinghua Yan  7 , Jianxun Qi  3 , George F Gao  1   2   3
Affiliations

Structural basis of anti-PD-L1 monoclonal antibody avelumab for tumor therapy

Kefang Liu et al. Cell Res. 2017 Jan.
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Detailed binding of avelumab to hPD-L1 for the blockade of hPD-1/hPD-L1 interaction. (A) Overall structure of the hPD-L1/avelumab-scFv complex. hPD-L1 (only the mAb-binding IgV domain is depicted) is shown as surface diagram in light blue, and the heavy (VH) and light (VL) chains of scFv are shown as cartoon representations in pink and cyan, respectively. The CDR1, CDR2 and CDR3 loops of VH are colored in yellow, green and hot pink, respectively. The CDR1 and CDR3 loops of VL are colored in purple and blue, respectively. (B) The epitope residues in hPD-L1 are denoted in black characters. Residues contacted by the avelumab-scFv VH or VL are colored in pink and cyan, respectively, whereas residues contacted by both chains are colored in lemon. (C) The residues of avelumab-scFv contacting hPD-L1 are colored in yellow for VH and colored in magenta for VL. (D) The detailed interactions in hPD-L1/avelumab-scFv complex. Residues involved in the hydrogen bond interaction are shown as sticks and labeled. Hydrogen bonds are shown as dash lines. (E) Superposition of the hPD-L1/avelumab-scFv complex structure with hPD-1/hPD-L1 complex structure. hPD-1 is shown in orange and avelumab-scFv VH in pink, VL in cyan, respectively. (F) Binding surface of hPD-L1 by hPD-1 or avelumab. The binding residues on hPD-L1 are colored in orange, whereas residues contacted by the avelumab-scFv VH or VL are colored in pink or cyan, respectively, and the overlapping residues bound by both the receptor hPD-1 and avelumab are colored in red.
See this image and copyright information in PMC

References

    1. Powles T, Eder JP, Fine GD, et al. Nature 2014; 515:558. - PubMed
    1. Rosenberg JE, Hoffman-Censits J, Powles T, et al. Lancet 2016; 387:1909–1920. - PMC - PubMed
    1. Tan S, Gao GF. Chinese Sci Bull 2015; 60:3155–3157. (In Chinese)
    1. Callahan MK, Postow MA, Wolchok JD. Immunity 2016; 44:1069–1078. - PubMed
    1. Na Z, Yeo SP, Bharath SR, et al. Cell Res 2017; 27:147–150. - PMC - PubMed

Publication types